Poster presented at the College on Problems of Drug Dependence (CPDD) annual meeting, San Diego, CA, June 9-14, 2018.
Aimee N.C. Campbell, PhD, MSW (Columbia University, GNY Node), Celestina Barbosa-Leiker, PhD (Washington State University, PN Node), Sarah Mennenga, PhD (New York University School of Medicine, GNY Node), Mary A. Hatch-Maillette, PhD (University of Washington, PN Node), Martina Pavlicova, PhD (Trustees of Columbia University, GNY Node), Jennifer Scodes (Columbia University, GNY Node), Shannon Gwin Mitchell, PhD (Friends Research Institute, MA Node), Patricia Novo, MPA, MPH (New York University School of Medicine, GNY Node), Tanya Saraiya (Adelphi University), Edward V. Nunes, MD (Columbia University, GNY Node), Shelly F. Greenfield, MD, MPH (McLean Hospital, NEC Node).
This ancillary investigation of data from NIDA Clinical Trials Network protocol CTN-0051, a randomized, controlled trial comparing extended-release naltrexone to buprenorphine, examined baseline sex differences in men and women (N=570) with opioid use disorder (OUD) receiving inpatient services. Women were significantly younger; more likely to identify as bisexual, live with a sexual partner, and be financially dependent on someone else; and less likely to be employed. Women reported significantly greater psychiatric comorbidity and risk behaviors, and had shorter duration, but similar age of onset, of opioid use.
Conclusions: Findings underscore economic, psychiatric, and infection vulnerability among women with OUD, which may complicate treatment initiatiion, retention, and recovery. Interventions targeting these disparities should be explored. (Poster, PDF, English, 2018)
Keywords: Buprenorphine/Naloxone | CTN platform/ancillary study | Gender differences | Naltrexone | Opioid dependence | Pharmacological therapy | Women | College on Problems of Drug Dependence (CPDD) annual meeting, 2018
Document No: 1323.
Submitted by Patricia Novo, GNY Node, 7/30/2018.